Eyecheck

Empower science based natural nutrition for everyday eye health


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9



Eyecheck® is an eye health dietary supplement company. Working with clinicians, the company develops research backed nutritional supplements with the highest quality natural ingredients that are third party tested and certified, and meet GMP manufacturing standards. 

The company continues to demonstrate positive revenue growth with just two existing products:
Macutene® / Neuroptene®

                                              
In Q2 2021, Eyecheck® will launch Pristene®, a Direct-to-Consumer brand focused on providing distinct benefits to support daily vision and related
cognitive performance:

High Definition™ / For Sight™ / Perfect Pressure™



Current sales channels include e-commerce through eyecheck®.com, walmart.com and amazon.com.  Planned channel expansion in 2021 to include pristene.com, vitacost.com, amazon.com.uk and retail.

Global demand for vegan, natural supplements is expected to increase significantly over the next decade

86% of US adults take vitamins or supplements despite the fact many supplements are made with poor quality ingredients and poor manufacturing processes.

87% of U.S. adults have confidence in the safety, quality, and effectiveness of dietary supplements

77% of all supplements are purchased through Amazon.

Sources:
1. Grand View Research. Global Eye Health Supplements Market Report, 2020-2027
2. 2019 Harris Poll
3. Council for Responsible Nutrition Survey 2016
4. Slice Intelligence 2016  Results of on-line shopper survey



Eyecheck® is revolutionizing the eye care supplement industry by:

  • Formulating products by working directly with physicians and scientists using evidence-based, clinical research
  • Formulating products using ultra-premium ingredients and using manufacturers with strict quality controls
  • Obtaining independent certification of our products using our “Quadrinity”



More than 2 million doses delivered to US consumers



TONY MOSES, CEO
Nearly 39 years in the field of eyecare, engaged in both marketing and sales management activity in 126 countries. Expertise in both pharma and medical device industries in the field of eyecare.

RAMA JAGER, MD, CHIEF MEDICAL OFFICER
Founder of Eyecheck® and a board-certified ophthalmologist and vitreoretinal surgeon. Clinical Professor of Ophthalmology at the University of Illinois at Chicago.

LAUREN HARNEW, DIRECTOR OF OPERATIONS
Since joining the team in 2014, she has honed her skills in project management, product development, and operational efficiency. Prior to joining Eyecheck®, Lauren held a position at Roeda Signs, where she managed brand communications, customer relations, and product sales.

RAM PALANKI, PHARM. D., BOARD MEMBER
Nearly 20 years of drug development and commercialization experience in biopharmaceutical industry.  Expertise in building and operationalizing commercial infrastructures and launching landmark drug therapies and devices in ophthalmology. Currently serving as Senior Vice President of commercial strategy and operations at REGENXBIO, a leader in AAV gene therapy, with responsibility for commercializing the product pipeline across ophthalmology, central nervous system, neuromuscular and metabolic disease franchises

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.